Mefenamic Acid Manufacturing Plant Project Report 2025: Market by Region, Market by Application, Key Players, Pre-feasibility, Capital Investment Costs, Production Cost Analysis, Expenditure Projections, Return on Investment (ROI), Economic Feasibility, CAPEX, OPEX, Plant Machinery Cost

Mefenamic Acid Manufacturing Plant Project Report 2025: Cost Analysis & ROI

Mefenamic Acid Manufacturing Plant Project Report by Procurement Resource thoroughly focuses on every detail that encompasses the cost of manufacturing. Our extensive cost model meticulously covers breaking down Mefenamic Acid plant capital cost around raw materials, labour, technology, and manufacturing expenses. This enables precise cost structure optimisation and helps in identifying effective strategies to reduce the overall Mefenamic Acid manufacturing plant cost and the cash cost of manufacturing.

Planning to Set Up a Mefenamic Acid Plant? Request a Free Sample Project Report Now!
 

Mefenamic Acid is a synthetic nonsteroidal anti-inflammatory drug (NSAID) belonging to the anthranilic acid derivatives class. It is mainly utilized as an active pharmaceutical ingredient (API) for the treatment of mild to moderate pain. Due to its strong analgesic and anti-inflammatory properties, it is considered an important and widely prescribed medication.
 

Applications of Mefenamic Acid

• Pain Relief (Analgesic) (60-70%): Mefenamic Acid is widely used for the short-term treatment of pain, particularly menstrual pain (dysmenorrhea). It is also effective for managing pain associated with dental procedures, headaches, and postoperative recovery.
• Anti-inflammatory (20-30%): It is prescribed to reduce inflammation and pain in conditions such as rheumatoid arthritis and osteoarthritis.
• Fever Reduction (Antipyretic) (5-10%): While not its primary use, it can also be administered to reduce fever.
   

Top 5 Manufacturers of Mefenamic Acid

• Pfizer Inc. (USA)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy's Laboratories (India)
• Cipla Inc. (India)
   

Feedstock for Mefenamic Acid and Value Chain Dynamics

The production cash cost of Mefenamic Acid is largely determined by the price and availability of its key chemical precursors. Conducting a detailed cost analysis of a Mefenamic Acid manufacturing facility is critical to assessing its overall economic viability.

• Raw Material Sourcing: The primary feedstocks are 2-chlorobenzoic acid (CBA) and 2,3-dimethylaniline (DMA). The price and purity of these chemical intermediates, along with the copper catalyst, constitute the largest component of manufacturing expenses.
• Energy and Utilities: The chemical synthesis process, mainly heating for the reaction, crystallisation, and drying stages, is energy-intensive. Energy and utility costs represent a significant part of the overall operating expenses (OPEX).
• Solvents and Chemicals: The use of organic solvents for the reaction and purification steps is a key variable cost. The cost of these solvents and the expense of their recovery or safe disposal are critical factors.
   

Market Drivers for Mefenamic Acid

The market for Mefenamic Acid is driven by its established therapeutic use and the increasing prevalence of the conditions it treats.

• Rising Prevalence of Inflammatory Conditions: The global increase in chronic inflammatory diseases like arthritis and other musculoskeletal disorders is a primary driver of demand for mefenamic acid.
• Growing Awareness of Pain Management: Increased focus on managing acute pain, especially menstrual pain, in both developed and developing countries boosts its market growth.
• Cost-Effectiveness of Generic Drugs: As a widely available generic medication, it offers a cost-effective treatment option, driving high-volume sales.
• Regional Market Details
  • Asia-Pacific: This region is the largest market for mefenamic acid, serving as a major hub for API production, mainly in India and China. Low raw material and labour costs, a large population, and a growing pharmaceutical industry drive both production and consumption.
  • North America: The market is mature, driven by a well-established healthcare system and a high prevalence of inflammatory disorders. Demand is stable, with a focus on both generic and branded formulations.
  • Europe: A significant market with a strong pharmaceutical sector. Demand is supported by high health consciousness, though it is subject to strict regulatory standards for APIs.
  • Latin America, the Middle East, and Africa: These are emerging markets where demand is growing due to improving healthcare infrastructure and rising disposable incomes.
     

CAPEX (Capital Expenditure) for a Mefenamic Acid Plant

The total capital expenditure (CAPEX) for a Mefenamic Acid facility is substantial due to the specialised equipment required for chemical synthesis. This high mefenamic acid plant capital cost serves as a significant barrier to entry for new manufacturers.

• Process and Plant Equipment (60-70% of total CAPEX): This includes the investment cost for specialised equipment such as glass-lined chemical reactors, crystallisers, centrifuges for separation, purification columns, and industrial drying units.
• Utility and Off-site Facilities (15-20%): This covers the cost of solvent recovery systems, wastewater treatment plants, and robust HVAC systems to maintain controlled manufacturing environments.
• Storage and Handling (10-15%): This includes specialised tanks and silos for storing liquid and solid raw materials, solvents, and the final powdered API.
• Supporting Infrastructure (5-10%): This includes the cost of quality control laboratories, administrative offices, and environmental compliance systems.
   

OPEX (Operating Expenses) for a Mefenamic Acid Plant

Controlling operating expenses (OPEX) is critical for profitability. The manufacturing plant cost analysis shows a clear breakdown of fixed and variable costs, which ultimately determines the final cost per metric ton (USD/MT).

• Raw Material Procurement (50-60% of total OPEX): The cost of sourcing 2-chlorobenzoic acid (CBA), 2,3-dimethylaniline (DMA), and the copper catalyst is the most significant variable cost.
• Solvents and Reagents (15-20%): The recurring cost of solvents and other chemical reagents used in synthesis and purification is a major variable cost.
• Energy Consumption (10-15%): The electricity and fuel required for heating reactors, running equipment, and drying the final product.
• Workforce Compensation (8-10%): Salaries for skilled chemists, engineers, and plant operators are a key fixed cost.
• Maintenance and Repairs (2-4%): Routine and preventative maintenance for complex machinery are essential fixed costs.
• Depreciation and Amortisation: These are non-cash charges that account for the plant's initial investment cost over its useful life and are crucial in the overall production cost analysis.
   

Manufacturing Process of Mefenamic Acid

This report provides a value chain evaluation for Mefenamic Acid manufacturing, including an in-depth production cost analysis focused on its industrial synthesis.
 

Production via Condensation

• This method of production involves the process of catalytic condensation by using copper as a catalyst to produce Mefenamic Acid as the product. The process is initiated by the reaction of 2-chlorobenzoic acid (CBA) and 2,3-dimethylaniline (DMA) in the presence of copper (II) acetate as a catalyst, which results in the formation of Mefenamic Acid as the final product.
   

Properties of Mefenamic Acid

Physical Properties:

• Appearance: It appears as an off-white or yellowish crystalline powder.
• Molecular Formula: C15H15NO2
• Molecular Weight: 241.29 g/mol
• Melting Point: 230 degree Celsius (with decomposition).
• Solubility: Practically insoluble in water; sparingly soluble in ethanol and chloroform.
• Odour: Odourless.
   

Chemical Properties:

• Basic Structure: An anthranilic acid derivative, belonging to the fenamate class of NSAIDs.
• Acidity/Basicity: It is an acidic compound due to the carboxylic acid (COOH) functional group.
• Stability: It remains stable under normal storage conditions but is sensitive to light.
• Key Functional Groups: Carboxylic acid, secondary amine, and a dimethylphenyl group.
• Reactivity: The carboxylic acid group can react with bases to form salts, which are often used in pharmaceutical formulations to improve solubility.
   

Mefenamic Acid Manufacturing Plant Report provides you with a detailed assessment of capital investment costs (CAPEX) and operational expenses (OPEX), generally measured as cost per metric ton (USD/MT). This approach ensures that your investment decisions are aligned with the latest industry standards and economic feasibility metrics, enhancing your manufacturing efficiency and financial planning.
  
Apart from that, this Mefenamic Acid manufacturing plant report also covers the leading technology providers that help you plan a robust plan of action related to Mefenamic Acid manufacturing plant and its production process, and also by helping you with an in-depth supplier database. This report provides exclusive insights into the best manufacturing practices for Mefenamic Acid and technology implementation costs. This report also covers operational cash flow, fixed and variable costs, and detailed break-even point analysis, ensuring that your manufacturing process is not only efficient but also economically viable in the competitive market landscape.

In addition to operational insights, the Mefenamic Acid manufacturing plant report also comprehensively focuses on lifecycle cost analysis, maintenance costs, and energy consumption costs, which are critical for maintaining long-term sustainability and profitability. Our manufacturing cost analysis extends to include regulatory compliance costs, inventory holding costs, and logistics and distribution costs, providing a holistic view of the potential expenses and savings.

We at Procurement Resource ensure that this report is not only cost-efficient, environmentally sustainable, and aligned with the latest technological advancements but also that you are equipped with all necessary tools to optimise supply chain operations, manage risks effectively, and achieve superior market positioning for Mefenamic Acid.
 

Key Insights and Report Highlights

Key Questions Covered in our Mefenamic Acid Manufacturing Plant Report

• How can the cost of producing Mefenamic Acid be minimised, cash costs reduced, and manufacturing expenses managed efficiently to maximise overall efficiency?
• What is the estimated Mefenamic Acid manufacturing plant cost?
• What are the initial investment and capital expenditure requirements for setting up a Mefenamic Acid manufacturing plant, and how do these investments affect economic feasibility and ROI?
• How do we select and integrate technology providers to optimise the production process of Mefenamic Acid, and what are the associated implementation costs?
• How can operational cash flow be managed, and what strategies are recommended to balance fixed and variable costs during the operational phase of Mefenamic Acid manufacturing?
• How do market price fluctuations impact the profitability and cost per metric ton (USD/MT) for Mefenamic Acid, and what pricing strategy adjustments are necessary?
• What are the lifecycle costs and break-even points for Mefenamic Acid manufacturing, and which production efficiency metrics are critical for success?
• What strategies are in place to optimise the supply chain and manage inventory, ensuring regulatory compliance and minimising energy consumption costs?
• How can labour efficiency be optimised, and what measures are in place to enhance quality control and minimise material waste?
• What are the logistics and distribution costs, what financial and environmental risks are associated with entering new markets, and how can these be mitigated?
• What are the costs and benefits associated with technology upgrades, modernisation, and protecting intellectual property in Mefenamic Acid manufacturing?
• What types of insurance are required, and what are the comprehensive risk mitigation costs for Mefenamic Acid manufacturing?